Progress for targeting adenosine A2A receptors in cancer immunotherapy
10.16438/j.0513-4870.2022-0199
- VernacularTitle:靶向腺苷A2A受体的肿瘤免疫治疗研究进展
- Author:
Zhi-jing ZHANG
1
;
Qi-yi ZHANG
1
;
Zu-yi JIN
1
;
Kai ZHU
2
;
Wen DING
1
;
Xiao-lei ZHANG
1
Author Information
1. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
2. Changchun University of Chinese Medicine, Changchun 130117, China
- Publication Type:Research Article
- Keywords:
immunotherapy;
tumor microenvironment;
adenosine receptor;
A2AR inhibitor;
cancer immunotherapy drug
- From:
Acta Pharmaceutica Sinica
2022;57(9):2557-2569
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has completely changed the paradigm of clinical tumor treatment, but immune checkpoint inhibitors still have low objective response rates and are prone to drug resistance for most solid tumors. The immune suppression tumor microenvironment and complicated tumor immune escape mechanisms are key factors that affect the clinical outcome and response rates. Therefore, it is critical to reverse the obstacle of the tumor microenvironment to improve immunotherapy efficacy. The immune suppression caused by the increased level of adenosine in the tumor microenvironment raises the attention of people. Targeting adenosine receptors, especially A2AR, will be an effective strategy to improve immunotherapy efficacy. Targeting the adenosine-A2A pathway can increase immune infiltration, enhance immune cell function, and partially reverse immunotherapy-insensitive "cold tumors" to "hot tumors" to enhance treatment response rates and improve the efficacy of current immunotherapy. At present, many adenosine receptor inhibitors have shown good results in clinical trials, especially in combination with immune checkpoint inhibitors, chemotherapy, and adoptive cell transfer therapeutic drugs, which are expected to be used for tumor immunotherapy to bring new breakthroughs. This article reviews the accumulation mode of adenosine in the tumor microenvironment, the role of A2AR and their regulatory mechanism in immune response, the progress of A2AR inhibitors in clinical trials, potential risks to target A2AR, and the prospects for therapeutic targeting A2AR.
